Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.
Also called NCT05888103
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 207 participants
- Sponsor
- Registry
-
NCT05888103
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05888103. Randomized; quadruple masking; primary purpose treatment. Start 2023-07-11 (actual); primary completion 2024-04-02 (actual). Results posted on 2025-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
- Acronym
- V-Mono China
- Condition
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- Intervention (Drug)
- Inclisiran
- Intervention (Drug)
- Matching Placebo for Inclisiran
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05888103- Content hash
e9ad5b45a7019580f1d7d5ffcb19fdf0fd9546af1efd5a556c19b325cb4eef06